Aprea Therapeutics, Inc. (APRE)
NCM · Healthcare · Biotechnology
$0.69
-10.33%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$8.5M
Shares Outstanding
12.4M
Exchange
NCM
Currency
USD
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -3.4M | -3.1M | -2.6M | -3.4M |
| Net Income | -3.2M | -3.0M | -2.5M | -3.3M |
| Diluted EPS | $-0.53 | $-0.47 | $-0.32 | $-0.22 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -37.4M | -15.5M | -14.3M | -13.2M |
| Net Income | -112.7M | -14.3M | -13.0M | -12.6M |
| Diluted EPS | $-67.99 | $-3.95 | $-2.35 | $-1.93 |